Kolon Life Science Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 149.71 million compared to KRW 109.54 million a year ago. Net loss was KRW 30,726.34 million compared to net income of KRW 2,133.31 million a year ago.

Basic loss per share from continuing operations was KRW 2,944 compared to basic earnings per share from continuing operations of KRW 352 a year ago. Basic loss per share was KRW 2,692 compared to basic earnings per share of KRW 187 a year ago. Diluted loss per share was KRW 2,717 compared to diluted earnings per share of KRW 163 a year ago.